Investigational drug · Phase 3
HLX87
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2 + Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "HLX87"
First trial start
2026
Jan 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX87", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2 + Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX87" as an intervention, largest first.
- A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07294534 · 817 participants (planned) · Start Jan 27, 2026 · Primary completion Sep 30, 2028
Drug: HLX87+HX22; HLX87 + Pertuzumab and 1 more · For: HER2 + Breast Cancer
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerPivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT07294508 · 706 participants (planned) · Start Feb 27, 2026 · Primary completion Jan 15, 2028
Drug: HLX87 + HLX22; HLX87 + Pertuzumab and 2 more · For: HER2 + Breast Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HER2 + Breast Cancer
- HLX22Phase 34 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer
- HX22Phase 31 trial
Shanghai Henlius Biotech · HER2 + Breast Cancer
- IAM1363Phase 21 trial
Iambic Therapeutics, Inc · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.